Clinical Trial: Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: A Phase 2 Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax™ (rHuIL-12) in Healthy Subjects

Brief Summary: The purpose of this study is to determine whether HemaMax is safe and well tolerated to support efficacy under FDA's Animal Rule to reduce the morbidity and mortality associated with the hematopoietic syndrome of acute radiation syndrome.